Business
Roche bets USD 1.53 billion on Simcere’s trispecific T-cell engager
Roche has agreed to pay Simcere Pharmaceutical Group Limited (HKEX: 02096) USD 75 million upfront for global exclusive rights to SIM0660, a CD79a/CD19/CD3...
Leios hands Greater China rights to Phase III fat reduction drug to CMS
La Jolla, California-based Leios Therapeutics has signed an exclusive licensing agreement granting subsidiaries of China Medical System Holdings Limited...
Daiichi Sankyo advances AAX Biotech’s Opti-mAb into antibody program
Sweden-based AAX Biotech AB and Daiichi Sankyo (TSE: 4568) have advanced their research collaboration into an active antibody program following a successful...
Osivax and GC Biopharma combine T-cell and antibody approaches in single-shot flu vaccine
France-based Osivax and South Korea-based GC Biopharma (006280.KS) announced a long-term influenza vaccine collaboration to co-develop and commercialize a...
Samsung Biologics raises USD 2.2b to fund PolyPeptide acquisition and capacity expansion
South Korea-based Samsung Biologics (KRX: 207940.KS) announced a rights offering to raise KRW 3 trillion (approximately USD 2.2 billion), with the bulk of...
AusperBio raises USD 120m Series C for late-stage hepatitis B antisense therapy
AusperBio Therapeutics, a biopharmaceutical company focused on oligonucleotide therapies for chronic hepatitis B (CHB), has closed a USD 120 million Series...
Osivax pairs Phase II flu vaccine with GC Biopharma's marketed shot in combination deal
France-based Osivax and South Korea-based GC Biopharma (KRX: 006280) have announced a long-term collaboration to develop a single-injection combination...
Genentech taps DualityBio's DUPAC platform for multi-program ADC collaboration
Genentech has licensed DualityBio's DUPAC antibody-drug conjugate payload platform in a multi-program collaboration designed to generate next-generation...
SK Bio taps up Biohaven for Kv7 platform and epilepsy drug in USD 795m deal
SK Biopharmaceuticals has agreed to acquire an exclusive worldwide license to Biohaven Ltd.'s (NYSE: BHVN) Kv7 ion channel platform, including lead asset...
4basebio and Genezen integrate synthetic DNA platform into viral vector manufacturing workflow
UK-based 4basebio PLC (AIM: 4BB) and Indianapolis-based Genezen, a gene therapy contract development and manufacturing organization (CDMO), announced a...
ARCH, Population Health launch Sentivera around Haisco immunology asset in USD 1.5b deal
China-based Haisco Pharmaceutical Group (SZSE: 002653) has licensed a preclinical immunology asset to Sentivera, a newly formed US venture co-founded by...
Revier launches with EUR 6m bet on selective HDAC inhibition
Heidelberg, Germany-based Revier Therapeutics has closed a EUR 6 million seed financing round to advance a preclinical pipeline of selective class IIa...
Airway Therapeutics raises USD 50m to advance late-stage zelpultide alfa trial in BPD
Atlanta-based Airway Therapeutics, Inc. has closed a USD 50 million equity round to fund the late-stage clinical development of zelpultide alfa, a...
Roche continues obesity shopping with USD 2.3b deal for Hanmi’s UCN2 analog
Genentech has agreed to license HM17321, a urocortin-2 (UCN2) analog developed by South Korea-based Hanmi Pharm Co., Ltd. (KRX: 128940), in a deal worth up...
Anbogen taps University of Tokyo to explore new indications for ABT-301
Taiwan-based Anbogen Therapeutics Inc. (TPEx: 7784) entered a collaborative research agreement with the Laboratory of Veterinary Surgery, Graduate School of...
The AllSci Brief
Free, systematic R&D and deal news. Daily.